No, Ipamorelin doesnt directly increase testosterone
22,53 In the LEADER trial, which enrolled 9,340 patients with T2D at high cardiovascular risk, liraglutide demonstrated modest reduction in systolic BP (mean difference: 1.2 mm Hg
Always inform your healthcare provider about all supplements you are taking alongside GLP-1 medications
As of May 2026, retatrutide is in Phase 3 trials
Primary outcome The primary outcome, major adverse cardiovascular events (MACE), was reported in all 11 included studies, comprising of 91,490 participants with 4386 MACE events in the intervention group and 4884 MACE events in the placebo group
Program details and pricing may change